Bank of America Corp DE Boosts Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Bank of America Corp DE raised its stake in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 160.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 597,319 shares of the company's stock after acquiring an additional 367,720 shares during the quarter. Bank of America Corp DE owned about 0.47% of Humacyte worth $3,016,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new position in shares of Humacyte in the 4th quarter valued at $74,000. Ameriprise Financial Inc. bought a new stake in Humacyte in the fourth quarter valued at about $58,000. Freestone Grove Partners LP acquired a new position in Humacyte in the fourth quarter valued at about $196,000. Northern Trust Corp lifted its stake in Humacyte by 11.5% in the fourth quarter. Northern Trust Corp now owns 901,194 shares of the company's stock valued at $4,551,000 after buying an additional 92,708 shares during the period. Finally, Beacon Pointe Advisors LLC grew its position in shares of Humacyte by 33.3% during the 4th quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company's stock worth $101,000 after buying an additional 5,000 shares during the period. Institutional investors own 44.71% of the company's stock.

Insider Buying and Selling

In related news, CFO Dale A. Sander acquired 20,000 shares of the company's stock in a transaction on Thursday, April 10th. The shares were acquired at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the purchase, the chief financial officer now owns 40,600 shares in the company, valued at approximately $62,118. The trade was a 97.09% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kathleen Sebelius bought 50,000 shares of the business's stock in a transaction dated Tuesday, April 8th. The stock was acquired at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the purchase, the director now directly owns 91,207 shares in the company, valued at approximately $120,393.24. The trade was a 121.34% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 83,993 shares of company stock valued at $118,224 over the last ninety days. 5.10% of the stock is owned by corporate insiders.

Humacyte Stock Up 0.8%

HUMA traded up $0.02 during trading on Wednesday, reaching $2.63. 4,882,977 shares of the stock traded hands, compared to its average volume of 3,786,374. The stock's 50-day moving average is $1.74 and its 200 day moving average is $3.25. Humacyte, Inc. has a 12 month low of $1.15 and a 12 month high of $9.79. The stock has a market capitalization of $407.96 million, a PE ratio of -1.96 and a beta of 1.64.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.09. The business had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.46 million. As a group, equities research analysts anticipate that Humacyte, Inc. will post -1.27 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. D. Boral Capital reiterated a "buy" rating and issued a $25.00 target price on shares of Humacyte in a report on Tuesday, May 13th. Benchmark cut their price target on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. HC Wainwright assumed coverage on shares of Humacyte in a research note on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price target for the company. Finally, Wall Street Zen raised shares of Humacyte from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.71.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.